EDITORIAL
J. Pharm. Pharm. Sci.
The need to redefine diabetic cardiomyopathy as a unique clinical entity that requires pharmacotherapy
University of Alberta, Edmonton, Canada
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Abstract
N/A
Summary
Keywords
Heart Failure, Diabetic cardiomyopathy, Type 2 Diabetes, energy metabolism, Diastolic dysfunction
Received
28 August 2025
Accepted
10 September 2025
Copyright
© 2025 King and Ussher. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: John R. Ussher, jussher@ualberta.ca
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.